Acumen Pharmaceuticals, Inc. (ABOS)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Daniel J. O'Connell M.B.A. | CEO & Director | 1.05M | -- | 1970 |
| Dr. James Doherty Ph.D. | President & Chief Development Officer | 730.78k | -- | 1968 |
| Mr. Matt Zuga | CFO & Chief Business Officer | 703.16k | -- | -- |
| Dr. Grant A. Krafft Ph.D. | Co-Founder | 42k | -- | -- |
| Dr. Caleb E. Finch Ph.D. | Co-Founder | -- | -- | -- |
| Dr. William L. Klein Ph.D. | Co-Founder | -- | -- | -- |
| Mr. Russell Barton M.S. | Chief Operating Officer | 223.68k | -- | 1959 |
| Ms. Kelly Carranza | Vice President, Finance & Accounting and Corporate Controller | -- | -- | -- |
| Ms. Alex Braun M.B.A. | VP & Head of Investor Relations | -- | -- | -- |
| Mr. Derek M. Meisner Esq., J.D. | Chief Legal Officer & Corporate Secretary | 752.95k | -- | 1971 |
Acumen Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 61
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Corporate Governance
Upcoming Events
August 11, 2025 at 12:30 PM UTC - August 15, 2025 at 12:30 PM UTC
Acumen Pharmaceuticals, Inc. Earnings Date
Recent Events
April 22, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission